Pacira - About the company
Pacira is a public company based in Parsippany Troy Hills (United States), founded in 2006. It operates as a Developer of injectable non-opioid products for post-surgical pain control. Pacira has raised $85M in funding from investors like Orbimed, MPM Capital and Sanderling Ventures. The company has 2780 active competitors, including 979 funded and 674 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Karyopharm and C4 Therapeutics.
Company Details
Developer of injectable non-opioid products for postsurgical pain control. The company's lead product is called EXPAREL (bupivacaine liposome injectable suspension). It has also developed DepoCyt(e)(cytarabine liposome injection) which is a sustained-release liposomal formulation of the chemotherapeutic agent cytarabine that is used for the intrathecal treatment of lymphomatous meningitis, a complication of lymphoma.
- Website
- pacira.com
- Email ID
- *****@pacira.com
- Phone Number
- +1 **********
- Registered Address
- Parsippany, New Jersey
Key Metrics
Founded Year
2006
Location
Parsippany Troy Hills, United States
Stage
Public
Total Funding
$85M in 3 rounds
Latest Funding Round
Ranked
40th among 2780 active competitors
Annual Revenue
$549M as on Dec 31, 2024
Employee Count
887 as on Jan 31, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Pacira
Pacira is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Jul 31, 2006 | $1 - $1M (as on Dec 20, 2022) | - | - | |
Nov 17, 2014 | $337M (as on Dec 31, 2018) | 712 (as on Dec 31, 2023) | - | |
Dec 21, 2006 | $549M (as on Dec 31, 2024) | 782 (as on Dec 31, 2024) | - |
Pacira's IPO details
Pacira got listed on Feb 03, 2011.
Click here to take a look at Pacira's IPO in detail
Sign up to download Pacira's company profile
Pacira's funding and investors
Pacira has raised a total funding of $85M over 3 rounds. Its first funding round was on Nov 17, 2008. Pacira has 8 institutional investors.
Here is the list of recent funding rounds of Pacira:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 07, 2017 | 4259316 | Post IPO | 7473275 | 5971287 | 6370027 | 3988395 |
May 03, 2012 | 6165601 | Conventional Debt | 8829531 | 3665938 | 9586885 | |
Nov 17, 2008 | 2812371 | Series A | 5979790 | 5014672 | 3469896 |
Access funding benchmarks and valuations. Sign up today!View details of Pacira's funding rounds and investors
Pacira's founders and board of directors
Founder? Claim ProfilePacira's employee count trend
Pacira has 887 employees as of Jan 26. Here is Pacira's employee count trend over the years:
Uncover Pacira's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Pacira's Competitors and alternates
Top competitors of Pacira include Jazz Pharmaceuticals, Karyopharm and C4 Therapeutics. Here is the list of Top 10 competitors of Pacira, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  Karyopharm 2008, Natick (United States), Public | Developer of small molecule drugs for the treatment of cancer and inflammatory disease | $98.4M | 75/100 | |
3rd |  C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 74/100 | |
4th | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 74/100 | ||
5th |  Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 74/100 | |
6th |  Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
7th |  Alector 2013, San Francisco (United States), Public | Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders | $215M | 74/100 | |
8th | _1545299782322.png) Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 73/100 | |
9th |  Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 71/100 | |
10th |  Zentalis 2014, New York City (United States), Public | Developer of small molecule therapeutics for cancer treatment | $147M | 70/100 | |
40th |  Pacira 2006, Parsippany Troy Hills (United States), Public | Developer of injectable non-opioid products for post-surgical pain control | $85M | 72/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Pacira's competitors? Click here to see the top ones
Pacira's Investments and acquisitions
Pacira has made 3 investments in companies including CarthroniX and CODA Biotherapeutics. Pacira has also acquired 3 companies including GQ Bio and Flexion Therapeutics.Here is the list of investments & acquisitions:
Filter this list
Filter this listDate of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Feb 27, 2025 | Acquisition | 2012 | Hamburg (Germany) | |
Apr 11, 2022 | Investments | 2015 | Lancaster (United States) | |
Dec 06, 2021 | Investments | 2014 | San Francisco (United States) |
Want to know more about where corporates are investing? Sign up today!See all investments and acquisitions by Pacira
Reports related to Pacira
Here is the latest report on Pacira's sector:
News related to Pacira
Filter this listMedia has covered Pacira for a total of 79 events in the last 1 year, 13 of them have been about company updates and 5 about people movement.
•
•
•
•
Pacira & LG Chem Partner to Expand EXPAREL Access in Asia-Pacific MarketsGlobeNewswire•Jan 13, 2026•Pacira, Lgchem
•
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 RevenuesGlobeNewswire•Jan 09, 2026•Pacira
•
DOMA Perpetual to Nominate Directors at Pacira BioSciences' 2026 MeetingPR Newswire•Dec 30, 2025•Pacira
•
•
DOMA Perpetual Urges Pacira BioSciences Board to Explore SaleBenzinga•Nov 11, 2025•Pacira, Doma Perpetual
•
•
Pacira BioSciences Receives Notice of ANDA Filing from Qilu Pharmaceutical for EXPARELGlobeNewswire•Oct 27, 2025•Pacira
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Pacira
Explore our recently published companies
- Utrecht Art - Cranbury based, 1949 founded, Acquired company
- hrm.de - Unfunded company
- National School of First Aid Training - 2011 founded, Public company
- cambia-consulting.co.uk - Unfunded company
- Clientify - Unfunded company
- Omniflux - Unfunded company
